Bevacizumab治疗湿性型年龄相关性黄斑变性疗效观察

Effect of Bevacizumab on Exudative Age-related Macular Degeneration

目的探讨Bevacizumab治疗湿性型年龄相关性黄斑变性的效果。方法我院20例(20眼)湿性型年龄相关性黄斑变性患者给予玻璃体腔内注射Bevacizumab治疗,观察术前、术后1周及术后1个月矫正视力,术前及术后1个月视网膜中心厚度。结果术后1周及术后1个月矫正视力较术前明显升高,差异有统计学意义(P<0.05);术后1个月视网膜中心厚度较术前明显降低,差异有统计学意义(P<0.05)。术后1个月18眼染料渗漏减少,2眼渗漏无减少。所有注射眼均未发生眼内炎、青光眼、视网膜脱离及血管阻塞等严重并发症。结论玻璃体腔内注射Bev-acizumab治疗湿性型年龄相关性黄斑变性可以显著提高视力,减轻黄斑水肿。

Objective To investigate the clinical efficacy and validity of Bevacizumab in the treatment of exudative age-related macular degeneration（AMD）.Methods Twenty eyes of 20 AMD patients received intravitreal injection of Bevacizumb（Avastin）.The best-corrected visual acuity（BCVA） before and 1-week and 1-month after the operation,and the central retinal thickness （CRT） before and one month after the operation were retrospectively observed.Results The BCVA was obviously improved 1-week and 1-month after the operation as compared with pre-operation（P0.05）.And the CRT 1-month after the operation decreased remarkably as compared with pre-operation（P0.05）.less leakage on FFAICGA was observed in 18 eyes one month after the operation,and no obvious improvement on FFAICGA leakage was found in 2 eyes.No adverse events such as endophthalmitis,glaucoma,retinal detachment,and angiemphrasis were found.Conclusion Intravitreal Bevaciumab injection can remarkably improve visual acuity and reduce macular edema in the treatment of exudative AMD.